Mergers & Acquisitions Mergers & Acquisitions

Danaher asked to divest assets, commit to R&D for GE Biopharma takeover in China decision

By Yonnex Li
  • 02 Mar 2020 00:50
  • 02 Mar 2020 01:24
US medical-equipment maker Danaher’s takeover of GE's biopharma unit has been approved by China's antitrust regulator, conditioned on a package of remedies including divestitures to mitigate the deal's impact on competition.

Notably, Washington, DC-based Danaher is required to commit to a research and development project for at least two years as part of

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News